Journal of Clinical and Experimental Hematopathology最新文献_第6页

Atypical lymphoplasmacytic and immunoblastic proliferation: A Systematic Review. 非典型淋巴浆细胞和免疫母细胞增生：系统综述。

IF 0.9

Journal of Clinical and Experimental Hematopathology Pub Date : 2024-01-01 DOI: 10.3960/jslrt.24007

Midori Filiz Nishimura, Toshiaki Takahashi, Kensuke Takaoka, Sharina Macapagal, Chalothorn Wannaphut, Asami Nishikori, Hiroko Toda, Yoshito Nishimura, Yasuharu Sato

{"title":"Atypical lymphoplasmacytic and immunoblastic proliferation: A Systematic Review.","authors":"Midori Filiz Nishimura, Toshiaki Takahashi, Kensuke Takaoka, Sharina Macapagal, Chalothorn Wannaphut, Asami Nishikori, Hiroko Toda, Yoshito Nishimura, Yasuharu Sato","doi":"10.3960/jslrt.24007","DOIUrl":"10.3960/jslrt.24007","url":null,"abstract":"Atypical lymphoplasmacytic and immunoblastic proliferation (ALPIBP) was first reported in 1984 as characteristic histological findings in lymph nodes associated with autoimmune diseases, but it has not been clearly defined to date. To summarize the histological characteristics and clinical diagnoses associated with ALPIBP, we searched MEDLINE and EMBASE for all peer-reviewed articles using keywords including \"atypical lymphoplasmacytic and immunoblastic lymphadenopathy\" from their inception to December 27, 2023. We also summarized the courses of three cases with a pathological diagnosis of ALPIBP. Nine articles with 52 cases were included. Among the total of 55 cases, including the three from our institution, the median age of the cases was 63.5 years with a female predominance (69.5%). Lymphadenopathy was generalized in 65.6% and regional in 34.4% of cases. RA (24.4%), SLE (24.4%), and autoimmune hemolytic anemia (20.0%), were common clinical diagnoses. A combination of cytotoxic chemotherapy was used in 15.6% of cases due to the suspicion of malignancy. Nodal T-follicular helper cell lymphoma, angioimmunoblastic type, methotrexate-associated lymphoproliferative disorders, and IgG4-related diseases were listed as important diseases that need to be pathologically differentiated from ALPIBP. This review summarizes the current understanding of the characteristics of ALPIBP. Given that underrecognition of ALPIBP could lead to overdiagnosis of hematological malignancy and unnecessary treatment, increased awareness of the condition in pathologists and clinicians is crucial.","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"64 2","pages":"97-106"},"PeriodicalIF":0.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11303958/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Highlights: Myeloid cells in lymphoid malignancies. 重点：淋巴恶性肿瘤中的髓系细胞。

IF 0.9

Journal of Clinical and Experimental Hematopathology Pub Date : 2024-01-01 DOI: 10.3960/jslrt.24076

Yoshihiro Komohara

引用次数: 0

Complex karyotype determined using conventional cytogenetic analysis is a poor prognostic factor in patients with multiple myeloma. 通过传统细胞遗传学分析确定的复杂核型是多发性骨髓瘤患者预后不良的一个因素。

IF 1.5

Journal of Clinical and Experimental Hematopathology Pub Date : 2024-01-01 DOI: 10.3960/jslrt.23047

Hideki Uryu, Yuko Mishima, Yuko Ishihara, Yuko Shirouchi, Nobuhiko Yamauchi, Mitsuhito Hirano, Kei Hirano, Yukako Teramoto, Kikuaki Yoshida, Dai Maruyama

{"title":"Complex karyotype determined using conventional cytogenetic analysis is a poor prognostic factor in patients with multiple myeloma.","authors":"Hideki Uryu, Yuko Mishima, Yuko Ishihara, Yuko Shirouchi, Nobuhiko Yamauchi, Mitsuhito Hirano, Kei Hirano, Yukako Teramoto, Kikuaki Yoshida, Dai Maruyama","doi":"10.3960/jslrt.23047","DOIUrl":"10.3960/jslrt.23047","url":null,"abstract":"High-risk cytogenetic abnormalities (HRCAs) influence the prognosis of multiple myeloma (MM). However, additional cytogenetic aberrations can lead to poor outcomes. This study aimed to clarify whether HRCAs and additional chromosomal abnormalities affect MM prognosis. Patients with newly diagnosed MM who were treated with novel agents were retrospectively evaluated. The primary objective was to assess the difference in progression-free survival (PFS) and overall survival (OS) between patients with/without HRCAs and between patients with/without complex karyotype (CK). The secondary objectives were to identify factors affecting PFS/OS and factors related to CK. HRCAs were defined as del(17p), t(4;14), t(14;16), and gain/amplification(1q) assessed using fluorescence in situ hybridization. CK was defined as ≥3 chromosomal abnormalities on G-banding. Among 110 patients, 40 had HRCAs and 15 had CK. In this study, survival durations between patients with/without HRCAs were similar, while the CK group had significantly poorer PFS/OS than the no-CK group (median PFS: 9 vs. 24 months and median OS: 29 vs. 97 months, respectively), and a poor prognostic impact of CK was maintained in patients with HRCAs. In multivariate analysis, CK was correlated with poor PFS/OS (hazard ratio [HR]: 2.39, 95% confidence interval [95% CI]: 1.22-4.66 and HR: 2.66, 95% CI: 1.10-6.45, respectively). Bone marrow plasma cell (BMPC) ≥60% (odds ratio [OR] = 6.40, 95% CI: 1.50-27.2) and Revised International Staging System III (OR = 7.53, 95% CI: 2.09-27.1) were associated with CK. Our study suggests that CK may contribute to the poor prognosis of MM. Aggressive disease status including high BMPC proliferation could be relevant to CK.","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"64 1","pages":"10-20"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11079984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140307301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Histiocytic neoplasms: a brief review and differential diagnosis. 组织细胞肿瘤：简要回顾与鉴别诊断。

IF 0.9

Journal of Clinical and Experimental Hematopathology Pub Date : 2024-01-01 DOI: 10.3960/jslrt.24031

Rin Yamada, Yoshihiro Komohara

引用次数: 0

TTMV::RARA-positive acute promyelocytic leukemia with marrow necrosis and central nervous system involvement at disease recurrence. TTMV::RARA阳性急性早幼粒细胞白血病复发时伴有骨髓坏死和中枢神经系统受累。

IF 0.9

Journal of Clinical and Experimental Hematopathology Pub Date : 2024-01-01 DOI: 10.3960/jslrt.24015

Zhao Wang, Jiaqi Chen, Juanxia Meng, Mingfeng Zhao, Hongxing Liu, Xia Xiao

引用次数: 0

Salivary gland swelling as a characteristic manifestation of local cytokine release syndrome after anti-CD19 chimeric antigen receptor T cell therapy: A case series. 唾液腺肿胀是抗 CD19 嵌合抗原受体 T 细胞治疗后局部细胞因子释放综合征的特征性表现：病例系列。

IF 0.9

Journal of Clinical and Experimental Hematopathology Pub Date : 2024-01-01 DOI: 10.3960/jslrt.24035

Saki Kawase, Masatoshi Sakurai, Kyoko Masuda, Yusuke Kubota, Takahide Shindo, Ami Inokuchi, Hiroyoshi Hayashi, Misa Nakayasu, Yuka Shiozawa, Tomohiro Hirai, Takahiro Inoue, Takayuki Fujii, Haryoon Kim, Yuya Koda, Jun Kato, Keisuke Kataoka

{"title":"Salivary gland swelling as a characteristic manifestation of local cytokine release syndrome after anti-CD19 chimeric antigen receptor T cell therapy: A case series.","authors":"Saki Kawase, Masatoshi Sakurai, Kyoko Masuda, Yusuke Kubota, Takahide Shindo, Ami Inokuchi, Hiroyoshi Hayashi, Misa Nakayasu, Yuka Shiozawa, Tomohiro Hirai, Takahiro Inoue, Takayuki Fujii, Haryoon Kim, Yuya Koda, Jun Kato, Keisuke Kataoka","doi":"10.3960/jslrt.24035","DOIUrl":"10.3960/jslrt.24035","url":null,"abstract":"Cytokine release syndrome (CRS) is the most common adverse event of chimeric antigen receptor T (CAR-T) cell therapy and is usually characterized by systemic symptoms such as fever, hypotension, and hypoxia. However, there have been several recent reports of local CRS characterized by cervical swelling. This localized syndrome can cause life-threatening laryngeal edema and requires early diagnostic treatment. Here we report 3 cases of local CRS where bilateral salivary gland swelling emerged following anti-CD19 CAR-T cell therapy for relapsed or refractory diffuse large B-cell lymphoma. Following tocilizumab treatment for systemic CRS, all patients exhibited cervical swelling. Physical examinations revealed significant swelling of the bilateral submandibular glands, and computed tomography scans showed substantial enlargement of the bilateral parotid and submandibular glands. Immediate treatment with dexamethasone effectively managed the potentially life-threatening laryngeal or pharyngeal edema, thereby preventing severe airway obstruction. This study has demonstrated, for the first time to our knowledge, that salivary gland enlargement is a common finding in local CRS. This observation suggests that physicians should continue to closely monitor the risk of developing cervical edema leading to life-threatening airway obstruction after systemic CRS, even in patients treated with tocilizumab. If salivary gland swelling is observed, it would be better to consider prompt evaluation and dexamethasone administration.","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"64 3","pages":"261-267"},"PeriodicalIF":0.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142356096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Computed tomography findings of idiopathic multicentric Castleman disease subtypes. 特发性多中心Castleman病亚型的计算机断层扫描表现。

IF 0.9

Journal of Clinical and Experimental Hematopathology Pub Date : 2024-01-01 DOI: 10.3960/jslrt.24053

Toshihiro Iguchi, Asami Nishikori, Yasuharu Sato, Midori Filiz Nishimura, Noriko Iwaki, Katsuhide Kojima, Takashi Asahara, Fumio Otsuka, Yoshinobu Maeda, Takao Hiraki

{"title":"Computed tomography findings of idiopathic multicentric Castleman disease subtypes.","authors":"Toshihiro Iguchi, Asami Nishikori, Yasuharu Sato, Midori Filiz Nishimura, Noriko Iwaki, Katsuhide Kojima, Takashi Asahara, Fumio Otsuka, Yoshinobu Maeda, Takao Hiraki","doi":"10.3960/jslrt.24053","DOIUrl":"10.3960/jslrt.24053","url":null,"abstract":"This study retrospectively evaluated the computed tomography (CT) findings of idiopathic multicentric Castleman disease (iMCD) at a single center and compared the CT findings of iMCD-TAFRO with those of iMCD-non-TAFRO. CT images obtained within 30 days before diagnostic confirmation were reviewed for 20 patients with iMCD (8 men and 12 women, mean age 52.8 ± 12.3 years, range 25-74 years). Twelve patients were diagnosed with iMCD-TAFRO, five with iMCD-idiopathic plasmacytic lymphadenopathy, and three with iMCD-not otherwise specified. CT images revealed anasarca and lymphadenopathy in all 20 patients. The iMCD-TAFRO group showed significantly higher frequencies of ascites (100% vs. 37.5%, P = 0.004), gallbladder wall edema (75.0% vs. 12.5%, P = 0.020), periportal collar (91.7% vs. 25.0%, P = 0.004), and anterior mediastinal lesions (non-mass-forming infiltrative lesions) (66.7% vs. 12.5%, P = 0.028). Para-aortic edema tended to be more frequent in patients with the iMCD-TAFRO group (83.3% vs. 37.5%, P = 0.062), while the absence of anterior mediastinal lesions tended to be more frequent in the iMCD-non-TAFRO group (16.7% vs. 62.5%, P = 0.062). These CT findings may have clinical implications for improving the accuracy and speed of iMCD diagnosis and differentiating iMCD-TAFRO from other subtypes.","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"64 4","pages":"292-296"},"PeriodicalIF":0.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11786149/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world outcomes of venetoclax and rituximab for chronic lymphocytic leukemia/small lymphocytic lymphoma: A retrospective analysis of nine Japanese cases. Venetoclax 和利妥昔单抗治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的实际效果：九例日本病例的回顾性分析。

IF 0.9

Journal of Clinical and Experimental Hematopathology Pub Date : 2024-01-01 DOI: 10.3960/jslrt.24014

Masuho Saburi, Takumi Nishikawa, Yasuhiko Miyazaki, Kazuhiro Kohno, Masanori Sakata, Kazuki Okuhiro, Toshiyuki Nakayama, Eiichi Ohtsuka, Masao Ogata

引用次数: 0

Insulin-like growth factor II mRNA binding protein 3 is highly expressed in primary diffuse large B-cell lymphoma of the CNS. 胰岛素样生长因子 II mRNA 结合蛋白 3 在中枢神经系统原发性弥漫大 B 细胞淋巴瘤中高度表达。

IF 0.9

Journal of Clinical and Experimental Hematopathology Pub Date : 2024-01-01 DOI: 10.3960/jslrt.24025

Kentaro Odani, Masakazu Fujimoto, Hirotake Fujii, Manduwa Saka, Kai Mizoguchi, Masahiro Hirata, Takaki Sakurai, Yasuhide Takeuchi, Sachiko Minamiguchi, Yoshiki Arakawa, Hironori Haga

{"title":"Insulin-like growth factor II mRNA binding protein 3 is highly expressed in primary diffuse large B-cell lymphoma of the CNS.","authors":"Kentaro Odani, Masakazu Fujimoto, Hirotake Fujii, Manduwa Saka, Kai Mizoguchi, Masahiro Hirata, Takaki Sakurai, Yasuhide Takeuchi, Sachiko Minamiguchi, Yoshiki Arakawa, Hironori Haga","doi":"10.3960/jslrt.24025","DOIUrl":"10.3960/jslrt.24025","url":null,"abstract":"Primary diffuse large B-cell lymphoma of the central nervous system (CNS-DLBCL) can be difficult to diagnose because of the limited amount of biopsy tissue. Here, we analyzed the utility of insulin-like growth factor II mRNA binding protein 3 (IMP3) immunohistochemistry (IHC) as an adjunctive diagnostic tool for CNS-DLBCL. IHC was performed on 57 biopsy samples (55 brain biopsy samples and two vitreous cell blocks) from 54 patients with CNS-DLBCL, including three biopsy samples initially diagnosed as negative or indeterminate for CNS-DLBCL. Additionally, IMP3 IHC was performed on 68 DLBCLs other than CNS-DLBCL and 12 inflammatory brain diseases. Cytoplasmic IMP3 expression was noted in ≥50% of tumor cells in 100% (57/57) of CNS-DLBCLs and 88.2% (60/68) of non-CNS-DLBCLs. In contrast, no IMP3-positive CD20-positive B cells were observed in the inflammatory brain disease (P < 0.0001). In conclusion, IMP3 is highly expressed in CNS-DLBCL. However, it is also expressed in other types of DLBCLs, making it less specific. Most CNS-DLBCL cases can be diagnosed without performing IHC for IMP3 expression, but it may be a useful adjunctive tool to differentiate from reactive lesions when tumor cells are few or deformed.","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"64 3","pages":"203-207"},"PeriodicalIF":0.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528255/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142356095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Frequent CDKN2B/P15 and DAPK1 methylation in duodenal follicular lymphoma is related to duodenal reactive lymphoid hyperplasia. 十二指肠滤泡淋巴瘤中CDKN2B/P15和DAPK1的频繁甲基化与十二指肠反应性淋巴增生有关。

IF 0.9

Journal of Clinical and Experimental Hematopathology Pub Date : 2024-01-01 DOI: 10.3960/jslrt.24020

Katsuyoshi Takata, Tomoko Miyata-Takata, Yasuharu Sato

{"title":"Frequent CDKN2B/P15 and DAPK1 methylation in duodenal follicular lymphoma is related to duodenal reactive lymphoid hyperplasia.","authors":"Katsuyoshi Takata, Tomoko Miyata-Takata, Yasuharu Sato","doi":"10.3960/jslrt.24020","DOIUrl":"10.3960/jslrt.24020","url":null,"abstract":"Duodenal type follicular lymphoma (DFL), a rare entity of follicular lymphoma (FL), is clinically indolent and is characterized by a low histological grade compared with nodal follicular lymphoma (NFL). Our previous reports revealed that DFL shares characteristics of both NFL and mucosa-associated lymphoid tissue (MALT) lymphoma in terms of clinical and biological aspects, suggesting its pathogenesis may involve antigenic stimulation. In contrast to NFL, the genomic methylation status of DFL is still challenging. Here, we determined the methylation profiles of DNAs from patients with DFL (n = 12), NFL (n = 10), duodenal reactive lymphoid hyperplasia (D-RLH) (n = 7), nodal reactive lymphoid hyperplasia (N-RLH) (n = 5), and duodenal samples from normal subjects (NDU) (n = 5) using methylation specific PCR of targets previously identified in MALT lymphoma (CDKN2B/P15, CDKN2A/P16, CDKN2C/P18, MGMT, hMLH-1, TP73, DAPK, HCAD). DAPK1 was frequently methylated in DFL (9/12; 75%), NFL (9/10; 90%), and D-RLH (5/7; 71%). CDKN2B/P15 sequences were methylated in six DFL samples and in only one NFL sample. Immunohistochemical analysis showed that p15 expression inversely correlated with methylation status. Genes encoding other cyclin-dependent kinase inhibitors (CDKN2A/P16, CDKN2C/P18) were not methylated in DFL samples. Methylation of the genes of interest was not detected in DNAs from D-RLH, except for DAPK1, and the difference in the extent of methylation between NDU and D-RLH was statistically significant (P = 0.013). Our results suggest that D-RLH serves as a reservoir for the development of DFL and that methylation of CDKN2B/P15 plays an important role in this process.","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"64 2","pages":"129-137"},"PeriodicalIF":0.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11303960/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0